RxSight, Inc.

NasdaqGM:RXST 株式レポート

時価総額：US$291.8m

RxSight マネジメント

マネジメント 基準チェック /24

RxSightの CEO はRon Kurtzで、 Jan2016年に任命され、 の在任期間は 10.33年です。 の年間総報酬は$ 6.98Mで、 9.7%給与と90.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.01%を直接所有しており、その価値は$ 5.85M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と4.8年です。

主要情報

Ron Kurtz

最高経営責任者

US$7.0m

報酬総額

CEO給与比率9.71%
CEO在任期間10.3yrs
CEOの所有権2.0%
経営陣の平均在職期間3.6yrs
取締役会の平均在任期間4.8yrs

経営陣の近況

Recent updates

RXST: Future Returns Will Rely On Reset 2026 Revenue Guidance

Analysts have trimmed RxSight's fair value estimate from about $10.21 to $9.93, reflecting recent price target adjustments after Q4 results and updated 2026 revenue guidance. Analyst Commentary Recent Street research around RxSight centers on updated price targets and the new 2026 revenue outlook, with opinions clustering around a more cautious but still engaged stance.

RXST: Future Returns Will Rely On New CFO And 2026 Revenue Guidance

Analysts now see RxSight's fair value edging up to about $10.21 per share from roughly $10.06, reflecting recent price target moves clustered around $9 to $10 as they incorporate updated 2026 guidance, Q4 results and leadership changes into their models. Analyst Commentary Recent research paints a mixed picture around RxSight, with price targets clustered around the high single digits and ratings generally sitting in the middle of the scale.

RXST: Future Returns Will Hinge On New CFO And 2026 Guidance

RxSight's updated fair value estimate has edged slightly lower, in line with Street price targets drifting from around $10 to a range centered near $9 to $10, as analysts factor in refreshed models, 2026 revenue guidance of $120M to $135M, and a mix of target cuts and raises that still cluster around neutral ratings. Analyst Commentary Recent research keeps RxSight broadly in neutral territory, with modest target changes reflecting updated revenue models, the new 2026 guidance range of $120M to $135M, and reactions to management changes.

RXST: Future Returns Will Hinge On New CFO And Execution Quality

Analysts have nudged their blended price target on RxSight lower to about $10.17 from $10.39, reflecting updated views on revenue growth, margins, and future P/E after recent neutral ratings and mixed target moves in the $9 to $10 range. Analyst Commentary Recent research paints a mixed picture for RxSight, with most firms holding neutral ratings and fine tuning their targets in a relatively tight range around the current blended estimate.

Is This Lens Maker Mispriced? A Blind Spot in Plain Sight

RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.

RXST: Future Returns Will Depend On New CFO And Execution Quality

Analysts have raised their average price target on RxSight by $1, citing the recent Piper Sandler move, a neutral initiation that adds coverage breadth, and supportive commentary around the new CFO appointment as reasons for a slightly refined outlook on growth, profitability, and future P/E expectations. Analyst Commentary Recent Street research on RxSight centers on how the new CFO, updated guidance commentary, and modest target changes feed into expectations for execution quality and valuation support.

RXST: Future Returns Will Hinge On New CFO And Execution Confidence

Analysts have nudged their price targets on RxSight modestly higher, with updated models pointing to slightly stronger revenue growth and profit margins and a marginally lower discount rate, while some recent research highlights a move to a $10 target and views the new CFO appointment as supportive of the story. Analyst Commentary Recent research on RxSight reflects a mix of cautious optimism and lingering questions around execution, valuation and the setup after recent share price moves.

RXST: Future Returns Will Depend On Comfortable Revenue And New CFO Execution

Analysts nudged their fair value estimate for RxSight slightly higher to about $10.39 from $10.33, citing better than anticipated recent quarters, a new CFO appointment they view positively, and Street research highlighting revenue that came in ahead of prior expectations, with longer term revenue forecasts described as comfortable. Analyst Commentary Recent Street research paints a mixed but generally constructive picture around RxSight, with attention on execution in recent quarters, the new CFO appointment, and how current revenue trends line up with existing expectations.

We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely

Jan 10
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely

RXST: Future Returns Will Hinge On Sustaining Comfortable Revenue Expectations

Analysts lifted their fair value estimate for RxSight to about $10.33 from $9.89 after a recent price target increase to $10.00. They pointed to a quarter they viewed as better than feared, with revenue of $30m above prior estimates and current Street revenue expectations that they describe as comfortable.

RXST: Future Returns Will Depend On Sustaining Recent Revenue Outperformance

Analysts modestly raised their price target on RxSight to $10 from $8, citing a quarter that exceeded revenue expectations and growing confidence that current Street forecasts for 2026 sales are achievable. Analyst Commentary Analysts are digesting the stronger than expected quarter and reassessing the balance between upside potential and execution risks for RxSight.

RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues

Dec 12
RxSight, Inc.'s (NASDAQ:RXST) 28% Price Boost Is Out Of Tune With Revenues

RXST: Future Performance Will Hinge On Sustaining Outperformance Amid Lawsuit Uncertainty

Analysts have increased their price target for RxSight by $2 to $10, citing stronger than expected quarterly revenue performance and a favorable outlook for future estimates. Analyst Commentary Analysts have shared insights following the latest quarterly results for RxSight, highlighting both the optimistic outlook and areas of caution as the company navigates its growth trajectory.

RXST: Future Performance Will Depend On Sustained Revenue Execution And Demand Consistency

Analysts have increased their price target for RxSight to $9.67 from $8.89, citing strong quarterly revenue performance well above expectations and expressing confidence in future revenue estimates. Analyst Commentary Following RxSight's latest quarterly results, analysts have highlighted several factors influencing their revised outlook for the company’s valuation and future performance.

Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop

Oct 11
Lacklustre Performance Is Driving RxSight, Inc.'s (NASDAQ:RXST) 25% Price Drop

The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?

Sep 22

Entry Into European And Asian Markets Will Unlock New Opportunities

RxSight’s consensus price target has been significantly reduced to $8.89 as analysts cite ongoing quarterly misses, slower customer adoption, plateauing utilization rates, and uncertainty around commercial strategy execution. Analyst Commentary Multiple bearish analysts cite consecutive quarterly misses and lowered guidance as primary concerns impacting RxSight's outlook.

Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Aug 07
Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%

Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

Jul 19
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook

The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

Jun 18
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
User avatar

South Korea And UK Approvals Will Expand Market Adoption

International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

Apr 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Mar 08
RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

Feb 28
RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target

The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

Dec 06
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye

Nov 29

We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Sep 04
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth

Investing In The Future Of Cataract Surgery: The RxSight Advantage

Aug 13

With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Aug 03
With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For

Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

Jul 12
Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching

RxSight: Great Business Model, Stretched Valuations

Jul 10

A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

Jun 20
A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)

RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

May 09
RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results

RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

May 05
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business

RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation

May 01

Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Apr 16
Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price

Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

Mar 24
Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?

RxSight Stock: Time To Refocus Following Eye Watering Rally

Jan 16

RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Jan 09
RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Dec 21
We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth

Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

Nov 24
Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%

CEO報酬分析

RxSight の収益と比較して、Ron Kurtz の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2025n/an/a

-US$39m

Sep 30 2025n/an/a

-US$36m

Jun 30 2025n/an/a

-US$32m

Mar 31 2025n/an/a

-US$27m

Dec 31 2024US$7mUS$678k

-US$27m

Sep 30 2024n/an/a

-US$31m

Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$44m

Dec 31 2023US$3mUS$633k

-US$49m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$62m

Dec 31 2022US$1mUS$563k

-US$67m

Sep 30 2022n/an/a

-US$67m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$5mUS$445k

-US$49m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

US$4m

Mar 31 2021n/an/a

US$17m

Dec 31 2020US$741kUS$310k

US$3m

報酬と市場: Ronの 総報酬 ($USD 6.98M ) は、 US市場 ($USD 1.56M ) の同規模の企業の平均を上回っています。

報酬と収益: Ronの報酬は増加しましたが、会社は利益を上げていません。

CEO

Ron Kurtz (62 yo)

10.3yrs
在職期間
US$6,982,453
報酬

Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 2016 and also se...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ronald Kurtz
President10.3yrsUS$6.98m2.01%
$ 5.9m
Ilya Goldshleger
Chief Operating Officer6.9yrsUS$5.82m0.19%
$ 562.4k
Eric Weinberg
Chief Business Development Officer10.9yrsUS$5.80m1.2%
$ 3.5m
Mark Wilterding
Chief Financial Officerless than a yearデータなし0.030%
$ 87.5k
Oliver Moravcevic
Vice President of Investor Relations2.5yrsデータなしデータなし
Jim Schindler
Executive VP & General Counselless than a yearデータなしデータなし
Scott Gaines
Chief Customer Officer4.3yrsデータなし0.036%
$ 105.0k
Maureen O'Connell
Executive VP of Clinical & Regulatory Affairs4.2yrsデータなしデータなし
Patrick Cullen
Executive VP of Quality & Infrastructure Operations3yrsデータなしデータなし
Adam Dashe
Executive Vice President of Internationalless than a yearデータなしデータなし
3.6yrs
平均在職期間
56yo
平均年齢

経験豊富な経営陣: RXSTの経営陣は 経験豊富 であると考えられます ( 3.6年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Ronald Kurtz
President10.3yrsUS$6.98m2.01%
$ 5.9m
William Link
Director9.5yrsUS$201.20k0.12%
$ 341.8k
Robert Palmisano
Independent Director4.8yrsUS$214.95k0.073%
$ 214.1k
Raymond Cohen
Independent Directorless than a yearデータなしデータなし
Juliet Bakker
Independent Director10.9yrsUS$214.95k0.094%
$ 275.3k
Jesse Corley
Independent Chairman of the Board11.3yrsUS$262.45k1.31%
$ 3.8m
Tamara Fountain
Independent Director4.3yrsUS$209.95k0.060%
$ 175.3k
Julie Andrews
Independent Director4.8yrsUS$219.95k0.073%
$ 214.1k
Robert Warner
Independent Director4.8yrsUS$217.45k0.073%
$ 214.1k
Shweta Maniar
Independent Director4.4yrsUS$204.95k0.018%
$ 52.2k
4.8yrs
平均在職期間
62.5yo
平均年齢

経験豊富なボード: RXSTの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/01 05:21
終値2026/05/01 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

RxSight, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15

アナリスト機関
Travis SteedBofA Global Research
Michael GormanBTIG
Xuyang LiJefferies LLC